The adult trial is interesting comparing Rem-L against SOC (we know who that is ... lol)
The other interesting comment about the adult GVHD rollout (assuming it passes or is better than SOC) is going to be handled internally by Mesoblast - no partner ? That will make a big difference to revenues not having to share revenues in this indication.
Ann: MSB Annual Financial Results and Operational Progress, page-16
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.015(1.04%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $3.815M | 2.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11031 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 14844 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |